The Development Program. (a) RELIANT hereby engages EURAND, and EURAND hereby agrees, to perform the work described in Exhibit A (the “Development Program”). In connection therewith, EURAND shall make its best efforts to carry out the Development Program in accordance with the timetables and budgets therein and shall make available such of its scientific, engineering, manufacturing and other personnel, necessary to perform its obligations in accordance with the terms hereof. Any material change in the Development Program shall be agreed to in writing between Eurand and RELIANT.
The Development Program. The parties shall undertake a development and manufacturing scale-up program for the Product, as described in the attached Exhibits B and C, with the overall objective of creating commercial-scale manufacturing capability and obtaining all regulatory approvals necessary for the commercialization of the Product (hereinafter, the *Confidential Treatment Requested. “Development Program”). Subject to the terms and conditions of this Agreement, including but not limited to Section 2.8 below, the parties will cooperate with each other using commercially reasonable good faith efforts to accomplish the goals of the Development Program; however, if the Product or associated processes are not successfully developed, neither party shall be liable to the other party solely by reason of that fact.
The Development Program. 14 5.1 Conduct of the Development Program ....................... 14 5.1.1. General .......................................... 14 5.1.2. Development Plan ................................. 15 5.1.3. Initial and Updated Development Plan ............. 15 5.1.4. Execution and Performance ........................ 16 5.1.5. Attendance at Regulatory Meetings ................ 16 5.2.
The Development Program. 11 4.1. Conduct of the Development Program............................................................ 11 4.1.1. General................................................................................ 11 4.1.2. Annual Development Plan............................................................... 11 4.1.3.
The Development Program. The Development Program shall have a term (the "Development Term") which commences upon the date an R&D Candidate is selected for Development and shall continue until the JSC agrees to cease the Development of the last remaining R&D Candidate or until all Regulatory Approvals for all R&D Candidates have been received in the Territory.
The Development Program. 5.1. Conduct of the Development Program.
The Development Program. Promptly following receipt of the amount set forth in Section 2 below, Institution shall use diligent efforts to develop Invader(R) polymorphism and mRNA transcript assays described in the Protocol, subject to Company providing Institution the materials described in Exhibit B (collectively, the "Company Materials"). Upon completion of the Development Program with respect to each such particular assay, Institution agrees to provide Company with the number of assay determinations set forth in the Protocol for such particular assay, including enzyme, buffer and Invader probes for such analyte (collectively, the "Institution Materials"). Accordingly, Institution shall, after consultation with Company, direct and perform the Development Program in a professional and diligent manner, all in accordance with the Protocol and the terms of this Agreement.
The Development Program. 4 2.1 GENERAL....................................................... 4 2.2
The Development Program. Xx. Xxxxxxx added, "The signing of this agreement with a prominent company in the field of circulatory disease management such as Cordis, is consistent with our strategy to establish Photoelectron as the leading company in the field of miniature x-ray technology accessing each new marketplace through strategic partnerships with market leaders. With Cordis as our strategic partner in this field, we feel we will be able to rapidly develop the system and penetrate the intravascular radiation therapy market." Conference Call Today Photoelectron Corporation will hold a conference call at 11:00 a.m. (Eastern Time) today. During the call, President and Chief Executive Officer Xxxx Xxxxxxx and Chief Financial Officer Xxxxxxx Xxxxx will discuss today's news release and be available to answer questions about other topics related to Photoelectron's strategy and opportunities. At 10:50 a.m. E.T., interested participants should call 0-000-000-0000 in the U.S. or 0-000-000-0000 internationally. There will also be a live Webcast of the call on the Investor Relations section of Photoelectron's Web site at xxx.xxxxxxxxxxxxx.xxx. About Photoelectron Founded in 1989 and based in Lexington, Mass., Photoelectron Corporation is a medical device and technology company specializing in miniature x-ray technology for the medical and industrial markets. The company has secured both regulatory approval and broad distribution channels for their current products. Photoelectron is leveraging its core expertise in miniature x-ray technology into distinct markets including cancer treatment, intravascular care, industrial x-ray, and radiation dosimetry products (xxx.xxxxxxxxxxxxx.xxx).
The Development Program. This Amended and Restated Development Program continues to capture improvements made within the District and permit tax increment financing for the Town’s bond debt service and economic development fund, as well as Rynel’s relocation and expansion costs. The TIF District will apply to the increase in assessed taxable personal property and taxable real estate value as a result of this project. Under the Original Development Program, the Town captures 100% of the increased assessed value over the original assessed value and retains within the District the new tax revenues generated by that portion of the new assessed value. The Original Development Program allocates a portion (35%) of TIF revenues to Rynel to defray the cost of its relocation and expansion. The Town retains the remaining portion (65%) of TIF revenues to be divided between bond debt service (40%) and an economic development fund (25%). The Original Development Program also states that in the event that the 40% of TIF revenues allocated to cover the Town’s bond debt service is insufficient in any given year, Rynel pays the difference. The term of the Original Development Program is twenty (20) years, ending after tax year 2024. The allocation of TIF revenues will change such that the captured assessed value associated with personal property shall be treated separately from the captured assessed value associated with real property. All property taxes paid on captured assessed value associated with personal property (“Personal Property TIF Revenues”) within the District, including any reimbursement from the State of Maine to the Town for exempt personal property located within the District, will be retained by the Town for use on Town economic development projects. In the event that the personal property within the District becomes fully taxable by the Town through an amendment to State statutes governing property tax exemptions, then the differentiation between Personal Property TIF Revenues and the TIF revenues relating to the captured assessed value of real property in the District (“Real Property TIF Revenues”) shall cease and all such TIF Revenues shall be governed by the terms described below for Real Property TIF Revenues. Any augmentations of the credit enhancement benefit provided under the original Development Program shall not become effective with respect to Rynel until Rynel has exercised its option to purchase the parcel comprising the District pursuant to Rynel’s lease dated Decem...
